Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAL regimen (mitoxantrone + cytarabine + lisaftoclax) for newly diagnosed adult AML
ChiCTR2600130735Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lisaftoclax in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoint: Composite complete remission (CR+CRi) rate after induction cycles. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600130735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130735.